A n important cause of morbidity and mortality in hospitalized patients with serious underlying conditions is candidemia, which is related to high health care costs (1, 2). However, the number of antifungal agents for candidemia treatment is small (azoles, echinocandins, flucytosine, and polyenes), and treatment failures have been reported. It is anticipated that antifungal susceptibility tests will be performed, particularly when this failure occurs, and additional epidemiological studies need to be performed. The Sensititre YeastOne (SYO) method is one of the antifungal susceptibility tests most frequently used in clinical laboratories. Clinical breakpoints (CBP) recommended by the CLSI have to be applied when tests are performed using that methodology. However, CBP are not available for the SYO method; therefore, in their absence, epidemiological cutoff values (ECVs) are useful for separation of isolates without mechanisms of resistance (wild-type [WT] from non-wild-type isolates, those that may harbor some resistance mechanisms [non-WT]), which is the goal of susceptibility tests. Several methods have been described to calculate ECVs; for instance, Arendrup et al. (3) estimated the ECVs as 2-fold dilution steps higher than the MIC 50 (the MIC that inhibits 50% of isolates); Rodriguez-Tudela et al. (4) worked with 2-fold dilutions above the modal MIC; Cantón et al. (5), Kronvall (6), and Turnidge et al. (7) calculated the ECVs by using statistical methods, and the latter two study groups concluded that the values thus obtained fit well with those determined through the MIC 50 or modal MIC methods. We previously reported the ECVs of echinocandins, amphotericin B, and flucytosine based on this methodology for the SYO method (5), and as an extension we have now determined the ECVs for the azole agents used for treatment of invasive Candida infections as recommended in the current guidelines (of the Infectious Diseases Society of America, FDA, etc.) (8).
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The aims of this study were to (i) define the WT MIC distributions of fluconazole (FZ), itraconazole (ITR), posaconazole (POS), and voriconazole (VOR) by the SYO method for four of the most common and two less common Candida species that cause bloodstream infections, (ii) propose the ECVs for each species-drug combination, and (iii) compare the ECVs obtained by the five methods with each other and also with those obtained using the CLSI methodology. Each isolate represented one infectious episode per patient and was identified by standard methods in each center, stored in a water suspension, and sent to the reference center (Hospital Universitario La Fe, Valencia, Spain) for posterior studies. C. parapsilosis and C. orthopsilosis strains were identified by a molecular methodology described elsewhere (9) . Three azoleresistant Candida strains with different mechanisms of resistance were used to assess the accuracy of the ECVs calculated (Table 1) (10, 11) .
MATERIALS AND METHODS

Isolates
Antifungal susceptibility testing. Susceptibility tests were performed at the participating hospitals on the first isolate from each candidemia episode by using the microdilution colorimetric SYO method, with the SYO-09 panel (TREK Diagnostic Systems, Cleveland, OH), as instructed in the commercial guidelines. The quality control strains C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 were first tested in each participating laboratory, and results were sent to the reference center. All MIC values were within the expected ranges.
Definitions. The definitions of the WT population and ECV were those reported previously by other authors (4, 12, 13) ; briefly, a WT organism was defined as a strain that did not harbor any acquired or mutational resistance mechanism to the particular antifungal agent being examined.
The ECV is the highest MIC value for the WT population. It is calculated by taking into account the MIC distribution, the modal MIC of each distribution, and the inherent variability of the test (usually within one doubling dilution), and it should encompass Ն95% of isolates. The number of isolates needed to calculate a representative ECV was not established, but there is a consensus among experts that recommends at least 50 strains from at least three to five different laboratories be included.
Statistical analysis. Data were analyzed with R software (version 2.14.2) (14) . Both on-scale and off-scale MICs were included, with the values left unchanged. In order to approach a normal distribution, the MICs were converted to log 2 values. Statistical ECVs were calculated following the methods described by Turnidge et al., by Kronvall, and by the clustering method using the Mclust Library for R (version 3.4.11), as previously described (5-7). Since the ECVs estimated fell within a continuous scale, values were rounded to the nearest highest dilution after reconversion to concentration units.
RESULTS AND DISCUSSION
The MIC data for each species, including those species with few isolates (less than 100), and each antifungal agent were obtained from more than five laboratories. The MIC results of the antifungal agents tested, which have been reported elsewhere (15), were similar to those observed by other authors who have used the SYO method (16) (17) (18) . Table 2 describes the WT MIC distributions of the four azoles tested. All MIC distributions were typical for WT organisms and covered three to five 2-fold dilution steps surrounding the modal MIC, except those of ITR (n ϭ 93) and POS (n ϭ 33) for C. orthopsilosis, for which only 1 dilution was above the modal MIC. were within the 2-fold dilutions. The median ECVs were, in general, equal to or two 2-fold dilutions higher than those of the CLSI value, with the exception of POS for C. tropicalis, for which the ECV was four 2-fold dilutions higher (2 versus 0.12 mg/liter). The ECVs obtained with the modal MIC and MIC 50 were in general lower than the values obtained when we applied the statistical methods; nevertheless, 100 and 91.7% of the cases, respectively, were within 1 dilution of the median ECV (Tables 3 and 4 ). The MIC values determined with the SYO method for Candida strains with different mutations used to confirm the validity of the ECVs are shown in Table 1 ; all methods used to calculate the ECVs classified the strains harboring mutations as non-WT. The ECVs obtained by the different methods were compared with each other and with those reported based on the CLSI methodology. Therefore, the median values for the five methods analyzed were those put forward as the tentative ECVs. Table 4 shows the level of agreement (within one and two 2-fold dilutions) between methods, as well as the cases where the difference was greater than two 2-fold dilutions, and it also includes the Pearson's correlation values. In general, the agreement was Ն95.7%. The most repetitive exception was the ECV of POS for C. tropica- lis, for which the CLSI ECV was 3 to 5 dilutions lower than those obtained with the other methods. The Pearson's correlation between the median ECV from the SYO method and each of the other methods was very good (Ն0.94), except for that from the clustering method (0.89) ( Table  4 ). In a comparison of the ECVs from the CLSI method with those obtained with the SYO method for each antifungal agent, FZ showed the best correlation (Ͼ0.96), and when we compared species, the lowest correlation was for C. tropicalis. This species also showed the lowest Pearson's correlation for the echinocandin ECVs with the SYO method (5) .
The ECVs were also calculated for the distribution of the two sources of isolates individually, i.e., 1,262 isolates from 43 laboratories and 857 isolates from 1 center. The same result occurred with the echinocandin ECVs, and the results obtained were, in general, the same as those found with all 2,119 isolates, or they fell within one 2-fold dilution, which is in agreement with the work of Turnidge et al. and Kronvall, who reported that their methods are also valid for data sets generated by a single laboratory and method (6, 7) . Just as we emphasized in the determination of echinocandin ECVs with the SYO method, it is difficult to establish which statistical method best defines the ECV, due to the scarcity of resistant isolates. Perhaps the optimal method depends on the heterogeneity of the agent's MIC distributions, since different species may have different numbers of subpopulations and, consequently, different MIC distribution shapes (unimodal, bimodal, or multimodal). In fact, the majority of differences, in general, were only within one 2-fold dilution, and furthermore, the Pearson's correlation values between methods were good, and so we propose that the median values of the five methods used in this evaluation be considered the tentative ECVs for the SYO method. Moreover, independently of the method used, a 5% risk of misidentification was always assumed (in fact, it is 2.5%, because the distribution has two tails). In general, all ECVs determined with the five methods included Ն94% of isolates; the exceptions were the ECVs of FZ and VOR for C. parapsilosis and C. orthopsilosis. Other authors have also reported ECVs that did not include 95% of isolates (19, 20) .
The tentative ECVs proposed are very similar to those of the CLSI; the differences in some values are the same as those found when comparing MIC values obtained with the CLSI or SYO methodology (16) (17) (18) . The advantage of this study is that all isolates used were obtained from patients without prior treatment with any of the antifungal agents tested; thus, the outlier isolates probably represented mutant strains. The data came from 43 laboratories, and all isolates were obtained from blood cultures. Among the limitations of the study are the small numbers of C. krusei and C. orthopsilosis isolates tested, but we have kept the tentative ECVs for these species, for comparison among methods. Moreover, all isolates came from just one country, and so these values may not be completely representative but could be shared with other data sets in the future to establish forthcoming ECVs with the SYO method. The low number of strains with known mechanisms of resistance was another limitation. Nevertheless, these data have corroborated the ECVs obtained. We propose, for the first time, tentative ECVs for the SYO method and azole agents to help in monitoring the emergence of isolates with decreased susceptibilities to these agents, which is the aim of susceptibility tests and also of generation of ECVs.
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